Toronto Memory News Today

Could a new model of testing and drugs make this brain disease as treatable as Type 2 diabetes? As researchers run tests to find out, neuroscience is divided on what to do for now

The relentless pursuit of detecting Alzheimer's has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.

The relentless pursuit of detecting Alzheimer’s has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2023--

– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile – – Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions –

- Expert panel to provide proactive, evidence-informed recommendations that are costed and implementable - A panel of 17 leading experts in dementia care

Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.

/CNW/ - Research out of the University of Southern California released yesterday, World Alzheimers Day, found that Ontario could save up to $9.9 billion in...

A virtual event is coming up on Thursday, to highlight Alzheimer's Awareness month. Debbie Burns the Program C...